KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Gains from Investment Securities: 2018-2025

Historic Gains from Investment Securities for Castle Biosciences (CSTL) over the last 3 years, with Jun 2025 value amounting to $2.2 million.

  • Castle Biosciences' Gains from Investment Securities rose 253.17% to $2.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $12.4 million, marking a year-over-year increase of 128.13%. This contributed to the annual value of $8.8 million for FY2024, which is 70.67% up from last year.
  • According to the latest figures from Q2 2025, Castle Biosciences' Gains from Investment Securities is $2.2 million, which was down 13.64% from $2.5 million recorded in Q1 2025.
  • Castle Biosciences' Gains from Investment Securities' 5-year high stood at $6.4 million during Q4 2024, with a 5-year trough of -$20.4 million in Q2 2022.
  • Its 3-year average for Gains from Investment Securities is $2.2 million, with a median of $1.7 million in 2024.
  • Over the last 5 years, Castle Biosciences' Gains from Investment Securities had its largest YoY gain of 7,863.64% in 2022, and its largest YoY loss of 112.17% in 2022.
  • Over the past 5 years, Castle Biosciences' Gains from Investment Securities (Quarterly) stood at $2.5 million in 2021, then plummeted by 112.17% to -$300,000 in 2022, then spiked by 1,438.33% to $4.0 million in 2023, then soared by 58.88% to $6.4 million in 2024, then soared by 253.17% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q2 2025, $2.5 million for Q1 2025, and $6.4 million during Q4 2024.